EP300 and non-small cell lung carcinoma: Overall, this study established the physiological and pathological significance of the EP300-AS1-PTBP1-PRMT5 axis in NSCLC progression, suggesting that EP300-AS1 mimetics or PTBP1 inhibition may represent promising therapeutic strategies for NSCLC.